Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Nov 11 (Reuters) – Pfizer said on Wednesday that Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment the drugmaker picked

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)